A Phase 4 interventional study of PCV13 and PCV13 in Pneumonia, sponsored by Beijing Minhai Biotechnology Co., Ltd. Completed at 1 site in China. Open to participants aged 2 Months to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-18.
Sponsored by Beijing Minhai Biotechnology Co., Ltd · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing 13-valent pneumococcal vaccine in Pneumonia — none open to participants now, none under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumonia.
Among the 11 studies testing 13-valent pneumococcal vaccine in Pneumonia, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 7 in phase 4, and was the 11th registered.
1,568 studies on the registry are indexed under Pneumonia; 267 are open to participants now.
Browse Pneumonia studies →None of the 11 studies testing 13-valent pneumococcal vaccine in Pneumonia is open now. The open studies under Pneumonia, anywhere →
13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →
Of the 158 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 41 take children under 18; 24 take healthy volunteers.
This study: 2 Months to 5 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2019.
This study's enrollment of 621 is above the median of 128 across 977 interventional studies indexed under Pneumonia.
Median enrollment 516 across the 11 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 11 have an industry lead sponsor. The 10 most frequent:
Beijing Minhai Biotechnology Co., Ltd is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Beijing Minhai Biotechnology Co., Ltd has 1 study filed under Pneumonia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing 13-valent pneumococcal vaccine in Pneumonia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn about persistence of immunity of PCV13 in healthy population aged 2 months, 7 months-5 years. The main questions it aims to answer are the percentage of subjects reached the IgG level of ≥0.35 µg/mL, GMCs level for IgG antibody, and SAEs from one month to 12 months after the last injection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: PCV13
Biological: PCV13
Biological: PCV13
Biological: PCV13
percentage of subjects reached the IgG level of ≥0.35 µg/mL
evaluation time: two years after the first dose for 2-5 years old group, two and three years after the first dose for 12-23 months group, two, three and four years after the first dose for 7-11 months group, two, three, four and five years after the first dose for 2 months group.
Time frame: 2-5 years after the first dose
GMCs level for IgG antibody
evaluation time: two years after the first dose for 2-5 years old group, two and three years after the first dose for 12-23 months group, two, three and four years after the first dose for 7-11 months group, two, three, four and five years after the first dose for 2 months group.
Time frame: 2-5 years after the first dose
Serious Adverse Events (SAE)
Time frame: one months to 12 months after the last injection
Ran from Sep 2019 to primary completion in Nov 2022, 37 months.
Of 49 phase 4 interventional studies under Pneumonia, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 37 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Beijing Minhai Biotechnology Co., Ltd